BACKGROUND AND PURPOSE: CAS or CEA for asymptomatic carotid stenosis is the focus of recently completed and ongoing randomized clinical trials. These techniques are widely utilized outside the setting of such trials. Therefore, our goal was to analyze the in-hospital stroke or death rates after CAS or CEA for asymptomatic stenosis that reflect current nationwide practice.
F
or asymptomatic subjects to benefit from carotid revascularization, 30-day stroke or death rates following CEA should be below 3%. Similar arguments hold for CAS. 1 Age increases morbidity and mortality after CAS, independent of symptom status. 2 With many US practices increasingly adopting CAS, we wondered whether the morbidity and mortality rates of CAS as currently practiced were within published guidelines for carotid revascularization and were comparable with those of CEA. The NIS is a stratified dataset of discharges from nonfederal US hospitals, reflecting 2006 and 2007 practice patterns. 3 
Materials and Methods
We used ICD-9 procedure codes to identify records for CAS (00.63) or CEA (38.12). ICD-9 diagnostic codes were used to identify asymptomatic precerebral stenosis as an indication for CAS/ CEA (including 433.10 and 433.30, while excluding transient ischemic attack, 435.9 or 362.34). NIS datasets for 2006 and 2007 were analyzed. The main outcome was determined by the discharge code for death, ICD-9 diagnostic code for postoperative stroke (997.02), or ICD-9 diagnostic code for postoperative cardiac complications (997.1).
Comorbid conditions were identified by using clinical classification software and included renal disease, myocardial infarction, CHF, COPD, diabetes, hypertension, valve disease, and contralateral stenosis. 4 Other characteristics included bilateral asymptomatic stenosis (ICD-9 diagnostic code 433.30), sex, race, tobacco use, atrial fibrillation (427.31), hyperlipidemia (272.x), hospital bed size, hospital teaching status, and hospital procedure volume by tertile. Data were analyzed by sample-weighted ANOVA by using SAS (SAS Institute, Cary, North Carolina). Variables with P Ͻ .2 after univariate analysis were included in the final multivariate model, except for year, which was included in the multivariate model. Total charges per discharge record are also captured in the NIS. Hospital costs were calculated by using group average all-payer inpatient cost-to-charge ratios. CI, 0.83-1.14). Therefore, data from both years were combined for final analysis, with year as a covariate. The overall probability of in-hospital stroke, cardiac complications, or death was 2.9% after CEA and 3.66% after CAS (Table 2 ; unadjusted OR, 1.27; 95% CI, 1.1-1.47). The likelihood of inhospital stroke or death following CEA was 1.16%, whereas the probability of a complication following CAS was 1.69% (unadjusted OR, 1.46; 95% CI, 1.18 -1.8).
Results

CAS
We examined complication rates in patients Ն80 years of age versus younger patients. On univariate analysis, the likelihood of in-hospital stroke, cardiac complications, or death after CEA was 2.7% for Յ79 years of age and 3.8% for Ն80 years of age (Fig 1A; unadjusted OR for age, 1.44; 95% CI, 1.27-1.64). For each age category, the likelihood of in-hospital stroke, cardiac complications, or death was higher after CAS, with a probability of 3.3% for Յ79 years of age and 4.9% for Ն80 years of age (unadjusted OR for age, 1.5; 95% CI, 1.12-1.2). In-hospital stroke or death after CEA was 1.1% for Յ79 years of age and 1.5% for Ն80 years of age ( Fig 1B; unadjusted OR, 1.41; 95% CI, 1.15-1.72). In comparison, the in-hospital stroke or death rate after CAS was 1.4% for Յ79 years of age and 2.7% for Ն80 years of age (unadjusted OR, 1.96; 95% CI, 1.31-2.93), also exceeding that of CEA for each age group.
In multivariate analysis, use of CAS versus CEA for carotid revascularization did not reach statistical significance for the composite end point of stroke, cardiac complications, or death ( Table 3 ). The interaction between procedure and age dichotomized at 80 years of age was not significant. However, the odds of stroke or death as a secondary end point (excluding cardiac complications) were increased after CAS. This increase was independent of age, comorbidities, demographic factors, and year (OR, 1.28; 95% CI, 1.03-1.58). The odds of in-hospital stroke or death were also increased for women. Several comorbid conditions (in particular, CHF and renal disease) also increased the likelihood of in-hospital stroke, cardiac complications or death, and in-hospital stroke or death. A history of MI, hospital bed size, and hospital teaching status increased the risk of an adverse event when cardiac complications were included in the composite end point. Race and year of procedure did not increase the odds of an adverse event.
Average and median hospital charges and costs for each procedure by year showed that CAS was more expensive than CEA (Table 4) . These values exclude the physician fees. Finally, we examined the proportions of CEA versus CAS procedures that were performed at hospitals providing both procedures. In individuals Ͻ80 years of age, 19.8% underwent CAS while 80.2% underwent CEA. The proportion of CAS procedures increased in subjects Ն80 years of age to 25.5% versus 74.5% who underwent CEA.
Discussion
Although the incidence of stroke, cardiac complications, or death was higher following CAS than following CEA regardless of age category, it did not reach statistical significance. However, the likelihood of stroke or death was higher after CAS than CEA for asymptomatic stenosis. In particular, inhospital stroke or death (without considering cardiac complications) after CAS for individuals Ն80 years of age approached the 3% benchmark beyond which there is no net benefit for asymptomatic revascularization. 1 The 30-day rates for CAS are likely higher than the 2.7% in-hospital rate, which would be consistent with a recent meta-analysis reporting a 3.3% (2.6%-4.1%) 30-day stroke or death rate following asymptomatic CAS.
2 Age Ͼ75-80 years had a pooled relative risk of 1.93 (95% CI, 1.66 -2.24). 2 For the asymptomatic subjects enrolled in CREST, the periprocedural composite end point of stroke, MI, or death was 3.5% (SE, 0.8%) following CAS and 3.6% (SE, 0.8%) following CEA. 5 These rates were not statistically significant. Our in-hospital composite end point of stroke, cardiac complications, or death after CEA was lower (2.9%) than that in CREST, while the composite end point was similar following CAS. While death rates after each procedure from CREST and this study were comparable, our probability of in-hospital stroke following either CAS or CEA was lower than the periprocedural data of CREST. Cardiac complications, not MI specifically, were available from the NIS; thus, we cannot speculate further on this end point. Finally, our data were consistent with the CREST results showing that the probability of perioperative stroke or death was higher in the CAS arm than the CEA arm. During the timeframe of this study, the American Academy of Neurology guidelines did not recommend carotid revascularization for asymptomatic patients Ն75 years of age, and the American College of Cardiology Foundation guidelines noted that there was no evidence to support CAS in asymptomatic patients of any age. 6, 7 In contrast to these guidelines, we found that asymptomatic octogenarians were nearly twice as likely to undergo CAS rather than CEA when compared with younger asymptomatic patients undergoing carotid revascularization in 2006 -2007 (11.4% versus 6.5%).
For 2006 -2007, the in-hospital economics of carotid revascularization favored CEA, as does the long-term lifetime costeffectiveness. 8 Physician fees were not included as part of the in-hospital costs. NIS charges represent what the hospital billed. Cost-to-charge ratios were used to estimate costs that include operating costs and capital-related costs. 9 Two large trials of CEA for asymptomatic carotid stenosis found no benefit for patients Ͼ68 (ACAS) and 75 years of age (ACST). 10 This is likely because subjects with asymptomatic stenosis derive modest benefits and only after several years.
11
Recent studies, including OXVASC, imply an even lower stroke risk for optimal medically managed asymptomatic carotid stenosis than reported by ACAS or ACST. 12 Our data, therefore, raise important questions regarding the current US practice of CAS in asymptomatic patients when considering the following: 1) A significant proportion are octogenarians, in whom CAS is not proved to be of benefit. 2) Paradoxically, asymptomatic octogenarians undergo CAS more frequently than younger patients. 3) The 2.7% in-hospital stroke or death rate of CAS in asymptomatic octogenarians suggests little or no improvement over the natural history of asymptomatic carotid disease, especially because this may actually underestimate the 30-day death and stroke rate, which should be lower than the benchmark 3%. A further consideration may be made to recommend the best medical treatment in asymptomatic octogenarians, in lieu of any revascularization procedure.
Our study has several limitations. The NIS represents all discharges from a stratified sample of nonfederal US hospitals. The ICD-9 code represents cardiac complications rather than postoperative MI. Practice patterns, selection biases, and outcomes may be different in hospitals excluded from NIS. There is the potential for unmeasured confounders and selection bias for CAS or CEA beyond the covariates already included in this model. Discharge coding practices and accuracy are a limitation in administrative datasets. Nonetheless, our results include the strength of a nationally representative sample.
Conclusions
These in-hospital data suggest that routine CAS in asymptomatic octogenarians should await further comparative epidemiologic and clinical trial data regarding CAS, CEA, and medical management of asymptomatic carotid stenosis.
